Targets of emerging therapies for viral hepatitis B and C. (Q36653655)

15 August 2017

1 reference

title

Targets of emerging therapies for viral hepatitis B and C. (English)

1 reference

15 August 2017

1 reference

Daniel Yerly

1

1 reference

15 August 2017

Loriana Di Giammarino

series ordinal

2

1 reference

15 August 2017

Florian Bihl

series ordinal

3

1 reference

15 August 2017

Andreas Cerny

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

1 reference

15 August 2017

10

1 reference

15 August 2017

6

1 reference

15 August 2017

833-850

1 reference

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C virus NS5A: tales of a promiscuous protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C virus and the immune system: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The natural history of hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Inhibition of hepatitis C virus replication by antimonial compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Inhibition of authentic hepatitis C virus replication by sodium stibogluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Limited humoral immunity in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B virus genotypes: comparison of genotyping methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The immune response during hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Prevention of hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Treatment options in HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Antiviral therapy: nucleotide and nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Anti-HBV specific beta-L-2'-deoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Variant of hepatitis B virus with primary resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.833

10.1517/14728222.10.6.833

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference